Cargando…

Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study

Recurrent infections of upper and lower respiratory tract have an important clinical and economic impact, which can be reduced through appropriate preventive measures, including the use of immunomodulating agents, such as OM-85, which proved to be effective and safe in both adults and children. Alth...

Descripción completa

Detalles Bibliográficos
Autores principales: Esposito, Susanna, Cassano, Michele, Cutrera, Renato, Menzella, Francesco, Varricchio, Alfonso, Uberti, Marzio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746428/
https://www.ncbi.nlm.nih.gov/pubmed/35985019
http://dx.doi.org/10.1080/21645515.2022.2106720
_version_ 1784849357266223104
author Esposito, Susanna
Cassano, Michele
Cutrera, Renato
Menzella, Francesco
Varricchio, Alfonso
Uberti, Marzio
author_facet Esposito, Susanna
Cassano, Michele
Cutrera, Renato
Menzella, Francesco
Varricchio, Alfonso
Uberti, Marzio
author_sort Esposito, Susanna
collection PubMed
description Recurrent infections of upper and lower respiratory tract have an important clinical and economic impact, which can be reduced through appropriate preventive measures, including the use of immunomodulating agents, such as OM-85, which proved to be effective and safe in both adults and children. Although OM-85 can be useful for the prevention of respiratory tract infections, it is still underused in clinical practice. In order to evaluate the level of awareness of the disease burden of recurrent respiratory infections in adults and children and to assess the level of agreement on the prophylactic and therapeutic approach to the disease, including the use of immunomodulants, a Delphi study was performed. A board of six experts in the field of respiratory infections was appointed to elaborate a series of statements covering four main topics (disease, prevention, OM-85, and future strategies), which were thereafter voted by a panel of 30 experts. Results showed that prevention is unanimously recognized as the most important intervention to reduce disease burden, and the use of immunomodulation to improve the effectiveness of vaccination is gaining increasing favor among clinicians. In this respect, OM-85 is recognized as the most studied immunomodulating agent currently available, whose efficacy and safety make it a valuable tool to optimize the management of recurrent respiratory infections in both adults and children. In particular, the combined use of OM-85 and influenza vaccine was recognized as an effective and safe approach to improve the current prevention strategies in order to reduce the burden of recurrent respiratory infections.
format Online
Article
Text
id pubmed-9746428
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-97464282022-12-14 Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study Esposito, Susanna Cassano, Michele Cutrera, Renato Menzella, Francesco Varricchio, Alfonso Uberti, Marzio Hum Vaccin Immunother Immunotherapeutics – Research Article Recurrent infections of upper and lower respiratory tract have an important clinical and economic impact, which can be reduced through appropriate preventive measures, including the use of immunomodulating agents, such as OM-85, which proved to be effective and safe in both adults and children. Although OM-85 can be useful for the prevention of respiratory tract infections, it is still underused in clinical practice. In order to evaluate the level of awareness of the disease burden of recurrent respiratory infections in adults and children and to assess the level of agreement on the prophylactic and therapeutic approach to the disease, including the use of immunomodulants, a Delphi study was performed. A board of six experts in the field of respiratory infections was appointed to elaborate a series of statements covering four main topics (disease, prevention, OM-85, and future strategies), which were thereafter voted by a panel of 30 experts. Results showed that prevention is unanimously recognized as the most important intervention to reduce disease burden, and the use of immunomodulation to improve the effectiveness of vaccination is gaining increasing favor among clinicians. In this respect, OM-85 is recognized as the most studied immunomodulating agent currently available, whose efficacy and safety make it a valuable tool to optimize the management of recurrent respiratory infections in both adults and children. In particular, the combined use of OM-85 and influenza vaccine was recognized as an effective and safe approach to improve the current prevention strategies in order to reduce the burden of recurrent respiratory infections. Taylor & Francis 2022-08-19 /pmc/articles/PMC9746428/ /pubmed/35985019 http://dx.doi.org/10.1080/21645515.2022.2106720 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Immunotherapeutics – Research Article
Esposito, Susanna
Cassano, Michele
Cutrera, Renato
Menzella, Francesco
Varricchio, Alfonso
Uberti, Marzio
Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study
title Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study
title_full Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study
title_fullStr Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study
title_full_unstemmed Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study
title_short Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study
title_sort expert consensus on the role of om-85 in the management of recurrent respiratory infections: a delphi study
topic Immunotherapeutics – Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746428/
https://www.ncbi.nlm.nih.gov/pubmed/35985019
http://dx.doi.org/10.1080/21645515.2022.2106720
work_keys_str_mv AT espositosusanna expertconsensusontheroleofom85inthemanagementofrecurrentrespiratoryinfectionsadelphistudy
AT cassanomichele expertconsensusontheroleofom85inthemanagementofrecurrentrespiratoryinfectionsadelphistudy
AT cutrerarenato expertconsensusontheroleofom85inthemanagementofrecurrentrespiratoryinfectionsadelphistudy
AT menzellafrancesco expertconsensusontheroleofom85inthemanagementofrecurrentrespiratoryinfectionsadelphistudy
AT varricchioalfonso expertconsensusontheroleofom85inthemanagementofrecurrentrespiratoryinfectionsadelphistudy
AT ubertimarzio expertconsensusontheroleofom85inthemanagementofrecurrentrespiratoryinfectionsadelphistudy